ABSTRACT
Recombinant proteins are fundamental to modern medicine, enabling research, diagnostics, and drug discovery, yet their access is often restricted by centralized manufacturing and cold-chain distribution. Decentralized, on-site biomanufacturing can enable research, provide resilience, and advance personalized medicine. Here, we introduce MANGO (MANufacturing on the GO), a purpose-built, open-source device designed for automated, benchtop cell-free protein synthesis and purification. Computer-controlled synthesis and purification are mediated through biomedical-grade pumps, valves, and a microchannel manifold, enabling rapid protein production directly at the point-of-use. To demonstrate MANGO’s utility, we produced and validated a diverse range of proteins, including nanobodies against SARS-CoV-2 and TNF, cloning enzymes, and diagnostic enzymes, with performance equivalent to their commercial counterparts. We further deployed MANGO in Brazil and Colombia to support patient trials for SARS-CoV-2 and dengue virus diagnostics. These results establish MANGO as a low-cost, portable platform that can democratize access to bioreagents in both high- and low-resource settings and, ultimately, expand participation in the bioeconomy.
Competing Interest Statement
Y.G., S.C., and K.P. are co-inventors of technologies related to FluoroPLUM and co-founders of LSK Technologies, Inc., now part of Nicoya. K.P. also co-founded En Carta Diagnostics Ltd., while K.P., A.T., and A.K. co-founded Liberum Biotech, Inc. S.J.R.d.S. and L.P. hold patents for the LAMP technology (BR 10 2019 027711 4, filed on December 23, 2019, and BR 10 2024 010869 8, filed on May 29, 2024). The other authors have declared no competing interests.
Funding Statement
This work was supported by funds to K.P. from Defense Research and Development Canada, the Canadian Safety and Security Program (contract 39903-200137), Canada's International Development Research Centre (IDRC), grant number IDRC 109434-001; IDRC grant number 109547-001; the Canadian Institutes of Health Research (CIHR) Foundation Grant Program (201610FDN-375469), and the CIHR Project Grant (CIHR 202403PJT-520192-BE2-CEAA-129834); the CIHR Canada Research Chair Program (950-231075 and 950-233107); the University of Toronto's Medicine by Design Initiative, which receives funding from the Canada First Research Excellence Fund. S.J.R.d.S. and J.R.J.V. received Research Mobility Awards (473621 to S.J.R.d.S. and J.R.J.V.), funded by the Emerging & Pandemic Infections Consortium (EPIC) at the University of Toronto, Canada. J.R.J.V. was supported by the Ontario Graduate Scholarship (OGS). I.A.I. was supported by the Precision Medicine Initiative (PRiME) at the University of Toronto with internal fellowship number PRMUHT2024-001, and by the CIHR with fellowship number 202410MFE-531769-419793. M.S. received support from EPIC with the Pfizer EPIC Convergence Postdoctoral Fellowship in Vaccinology. A.B. and C.G. also received support from the Colombian National Ministry of Science (Contract 648-2021). C.G. and A.B. received funding from the Faculty of Sciences at Universidad de los Andes, Colombia. The funders were not involved in the study design, data collection and analysis, decision to publish, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Board (REB) of the University of Toronto, Canada, gave ethical approval for this work. Institutional Review Board of HEMOPE-PE, Brazil, gave ethical approval for this work. Ethics Committee of Hospital Universitario Hernando Moncaleano Perdomo, Colombia, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Co-first authors.
Data availability
Source data supporting the findings of this study are included within this paper and the Supplementary Information. Detailed instructions for building the MANGO device are available on our GitHub repository, ensuring open access and reproducibility. DNA sequence information for the constructs and oligos used in this study can be found in Supplementary Data.
